Related references
Note: Only part of the references are listed.EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling
Chun-Ju Chang et al.
CANCER CELL (2011)
CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation
Terence Kin Wah Lee et al.
CELL STEM CELL (2011)
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway
Lioubov G. Korotchkina et al.
AGING-US (2010)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma
Judit Anido et al.
CANCER CELL (2010)
Mammalian Target of Rapamycin Activator RHEB Is Frequently Overexpressed in Human Carcinomas and Is Critical and Sufficient for Skin Epithelial Carcinogenesis
Zhi Hong Lu et al.
CANCER RESEARCH (2010)
miR-130b Promotes CD133+ Liver Tumor-Initiating Cell Growth and Self-Renewal via Tumor Protein 53-Induced Nuclear Protein 1
Stephanie Ma et al.
CELL STEM CELL (2010)
mTOR-Mediated Activation of p70 S6K Induces Differentiation of Pluripotent Human Embryonic Stem Cells
Charles A. Easley et al.
CELLULAR REPROGRAMMING (2010)
Epigenetic Regulation of Cancer Stem Cell Marker CD133 by Transforming Growth Factor-β
Hanning You et al.
HEPATOLOGY (2010)
Targeting Breast Cancer Stem Cells
Suling Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
Jun Sunayama et al.
STEM CELLS (2010)
Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells
Joshua C. Curtin et al.
ONCOTARGET (2010)
Molecular identification and targeting of colorectal cancer stem cells
Kristel Kemper et al.
ONCOTARGET (2010)
Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation
Timothy B. Campbell et al.
BLOOD (2009)
mTOR Signal and Hypoxia-Inducible Factor-1α Regulate CD133 Expression in Cancer Cells
Kazuko Matsumoto et al.
CANCER RESEARCH (2009)
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence
Zoya N. Demidenko et al.
CELL CYCLE (2009)
Rapamycin decelerates cellular senescence
Zoya N. Demidenko et al.
CELL CYCLE (2009)
mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging
Rogerio M. Castilho et al.
CELL STEM CELL (2009)
CD133+ Liver Cancer Stem Cells from Methionine Adenosyl Transferase 1A-Deficient Mice Demonstrate Resistance to Transforming Growth Factor (TGF)-β-Induced Apoptosis
Wei Ding et al.
HEPATOLOGY (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro
Amy M. McCord et al.
MOLECULAR CANCER RESEARCH (2009)
Epigenetic regulation of CD133 and tumorigenicity of CD133+ovarian cancer cells
T. Baba et al.
ONCOGENE (2009)
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α
A. Soeda et al.
ONCOGENE (2009)
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations
Anna Dubrovska et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Expansion of CD133-Expressing Liver Cancer Stem Cells in Liver-Specific Phosphatase and Tensin Homolog Deleted on Chromosome 10-Deleted Mice
C. Bart Rountree et al.
STEM CELLS (2009)
CD133 expression is an independent prognostic marker for low survival in colorectal cancer
D. Horst et al.
BRITISH JOURNAL OF CANCER (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events
Caterina Nardella et al.
GENES & DEVELOPMENT (2008)
Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma
W. Song et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species
Chong Chen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
H. Korkaya et al.
ONCOGENE (2008)
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
Anne-Pierre Morel et al.
PLOS ONE (2008)
ATF6α-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo
Denis M. Schewe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice
C. Bart Rountree et al.
HEPATOLOGY (2008)
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway
S. Ma et al.
ONCOGENE (2008)
Influence of oxygen tension on CD133 phenotype in human glioma cell cultures
Nadine Platet et al.
CANCER LETTERS (2007)
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
Jiangbing Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Identification and characterization of tumorigenic liver cancer stem/progenitor cells
Stephanie Ma et al.
GASTROENTEROLOGY (2007)
CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity
Shengyong Yin et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Identification and expansion of human colon-cancer-initiating cells
Lucia Ricci-Vitiani et al.
NATURE (2007)
A CD133-expressing murine liver oval cell population with bilineage potential
C. Bart Rountree et al.
STEM CELLS (2007)
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens
Jun Miki et al.
CANCER RESEARCH (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways
L. Liu et al.
ONCOGENE (2006)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Lars Zender et al.
CELL (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1
AR Tee et al.
FEBS LETTERS (2005)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
Dysregulation of the TSC-mTOR pathway in human disease
K Inoki et al.
NATURE GENETICS (2005)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
PK Majumder et al.
NATURE MEDICINE (2004)
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2
A Garami et al.
MOLECULAR CELL (2003)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Share Paper
